Microlab (RMS)

EU-based microfluidics manufacturing platform

Speed · IP Protection · EU-Based Production

Request Investment Deck Schedule Call

Microlab (RMS)

EU-based microfluidics manufacturing platform

Speed · IP Protection · EU-Based Production

Request Investment Deck Schedule Call

POSITIONING

Bridging Prototype to Production

Microlab (RMS) is an EU-based microfluidics manufacturing platform designed to accelerate deep-tech commercialization. We bridge the critical gap between laboratory prototypes and industrial-scale production.

Bridge to Production

Seamless transition from prototype to scalable manufacturing

EU-Based Manufacturing

Strategic location ensuring IP protection and compliance

MedTech / Biotech Focus

Specialized expertise in high-precision medical applications

MARKET GAP

The Microfluidics Manufacturing Gap

Current market players fail to address the specific needs of deep-tech startups and scale-up companies in the critical prototype-to-production phase.

Large Manufacturers

Slow & Inflexible

Traditional players lack agility for rapid prototyping and iterative development cycles.

Premium EU Players

Expensive

High-cost Western European facilities create prohibitive pricing for early-stage validation.

Niche Players

Slower / Less Efficient

Small-scale operations struggle with technical capabilities and process standardization.

Clear Market Opportunity

Deep-tech companies need a partner that combines speed, cost efficiency, and European manufacturing standards — a gap Microlab is uniquely positioned to fill.

OUR SOLUTION

Precision Manufacturing at Speed

Microlab delivers the agility of a startup with the reliability of an established manufacturer, optimized specifically for microfluidics applications.

Fast Prototyping Cycles

Accelerated iteration from design to physical prototype, enabling rapid validation and refinement.

Pilot & Mid-Scale Production

Flexible capacity to scale from initial batches to medium production volumes without switching partners.

EU Jurisdiction & IP Protection

Manufacturing within European legal framework ensures intellectual property security and regulatory compliance.

MedTech-Grade Processes

Quality control and manufacturing standards that meet stringent medical device requirements.

Fast Prototyping Cycles

Accelerated iteration from design to physical prototype, enabling rapid validation and refinement.

Pilot & Mid-Scale Production

Flexible capacity to scale from initial batches to medium production volumes without switching partners.

EU Jurisdiction & IP Protection

Manufacturing within European legal framework ensures intellectual property security and regulatory compliance.

MedTech-Grade Processes

Quality control and manufacturing standards that meet stringent medical device requirements.

COMPETITIVE ADVANTAGE

Why Microlab Wins

Four strategic differentiators that position us as the leading choice for microfluidics manufacturing in Northern Europe.

Speed

LDI Technology

Laser Direct Imaging technology enables rapid prototyping and shorter lead times compared to traditional photolithography methods.

Cost Efficiency

Baltic Production Advantage

Strategic location in the Baltic region provides competitive cost structure while maintaining EU quality standards and infrastructure.

EU + IP Protection

Security & Compliance

Operations within EU jurisdiction ensure robust intellectual property protection and adherence to European manufacturing regulations.

Strategic Positioning

Market Focus

Specialized expertise in microfluidics for MedTech and Biotech, serving an underserved market segment with precision and expertise.

PRODUCTS & CAPABILITIES

End-to-End Manufacturing

Complete manufacturing capabilities from design validation to finished devices, all under one roof.

DfM Audit

Design for Manufacturing analysis

Lithography

High-precision pattern transfer

Master Molds

Precision tooling fabrication.

Polymer Replication

COC, COP, PMMA materials

Surface Functionalization

Advanced surface treatments

Assembly & Sealing

Complete device integration

Quality Control

MedTech-grade inspection

7+

Core Capabilities

100%

EU Manufacturing

ISO

Quality Standards

7+

Core Capabilities

100%

EU Manufacturing

ISO

Quality Standards

TARGET MARKET

Strategic Market Focus

Clear beachhead strategy targeting high-value segments with strong IP protection and recurring revenue potential.

PRIMARY BEACHHEAD

MedTech / Diagnostics

Point-of-care diagnostics, lab-on-a-chip devices, and medical testing platforms requiring precision microfluidics.

High regulatory standards
Recurring revenue potential
Strong IP protection needs

SECONDARY MARKET

Biotech

Cell analysis, drug discovery, and research applications demanding reliable and scalable microfluidic components.

Research partnerships
Scale-up opportunities
Innovation-driven

GROWTH OPPORTUNITY

AgTech

Agricultural testing and environmental monitoring solutions leveraging microfluidic sensor technologies.

Emerging applications
Sustainability focus
Volume potential

Beachhead Strategy

Primary focus on MedTech/Diagnostics to establish market leadership, then expand to adjacent high-growth segments leveraging proven capabilities.

BUSINESS MODEL

Scalable Revenue Model

A structured approach that captures value at every stage of the product development lifecycle.

Customer Journey

1

DfM

Design for Manufacturing

Initial consultation and design optimization

2

Prototype

Prototyping

Rapid iteration and proof of concept

3

Validation

Testing and regulatory preparation

4

Pilot

Pilot Production

Small-batch manufacturing runs

5

Production

Scalable manufacturing volumes

Revenue Streams

PROJECT-BASED

Engineering Services

DfM consulting, design optimization, and technical advisory services

PER-ORDER

Pilot Batches

Small to medium production runs for validation and early market entry

RECURRING

Recurring Contracts

Long-term manufacturing agreements with established production volumes

Customer Lifetime Value

Our model creates sticky relationships: customers who start with DfM services typically progress through the entire funnel, generating recurring production revenue.

INVESTMENT THESIS

Strategic Investment Opportunity

Multiple converging trends create a compelling case for European microfluidics manufacturing.

Nearshoring Trend in EU

Growing demand for European manufacturing driven by supply chain resilience, geopolitical considerations, and IP security concerns.

Supply chain independence
Strategic autonomy
Reduced lead times

High Entry Barriers

Significant capital requirements, technical expertise, and quality certifications create defensible competitive moat.

Capital intensive
Technical know-how
Regulatory compliance

Platform Scalability

Core manufacturing capabilities applicable across multiple market segments with minimal marginal cost increase.

Horizontal expansion
Asset leverage
Operational efficiency

B2B Recurring Revenue

Long-term manufacturing partnerships generate predictable cash flows and high customer switching costs.

Customer stickiness
Predictable revenue
High LTV/CAC ratio

€15B+

Global Microfluidics Market

by 2028

12%

Annual Growth Rate

CAGR 2024-2028

EU

Strategic Location

30% of global market

€15B+

Global Microfluidics Market

by 2028

12%

Annual Growth Rate

CAGR 2024-2028

EU

Strategic Location

30% of global market

RISKS & VALIDATION

Transparent Risk Assessment

We address key risks head-on with clear mitigation strategies and validation milestones.

RISK

Capital Intensity

Manufacturing equipment and facility setup require significant upfront investment.

MITIGATION

Phased expansion approach aligned with customer traction

RISK

Long Sales Cycles

B2B deep-tech sales typically involve extended qualification and validation periods.

MITIGATION

Pipeline building with strategic early adopters

RISK

Customer Proof Required

Market validation through reference customers critical for scaling.

MITIGATION

Focus on beachhead segment with referenceable early wins

RISK

Execution Risk

Operational complexity in scaling while maintaining quality standards.

MITIGATION

Experienced technical team and proven processes

Q1 2026

First customer production run

Q2 2026

3+ reference customers

Q4 2026

Recurring revenue model validated

Key Validation Milestones

Q1 2026

First customer production run

Q2 2026

3+ reference customers

Q4 2026

Recurring revenue model validated

Key Validation Milestones

VISION

Leading Microfluidics Platform in Northern Europe

Our vision is to become the go-to manufacturing partner for deep-tech companies across Europe, enabling breakthrough innovations in healthcare, biotechnology, and beyond.